Australian Associated Press journalist Derek Rose has shared LTR Pharma’s story following the launch of our IPO last week.
Of the Company’s commercialisation plans, he wrote:
“Because the drug is already approved in a different form, LTR should have an easier time bringing SPONTAN® to market than companies seeking approval of an all-new medicine…SPONTAN® could be prescribed by Australian doctors by mid-2024, with a filing for full approval in the US and Australia by late 2024 or early 2025.”
LTR Pharma’s SPONTAN® nasal spray could be a game-changer for the 60% of men over 45 who face Erectile Dysfunction, delivering results in just 10 minutes, outpacing traditional oral medications, like Viagra.